Candel Therapeutics, Inc. (CADL) News
Track canonical SquawkNews coverage tagged to CADL, Candel Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Candel Therapeutics Reports 24.5-Month Median Overall Survival in Phase 2a NSCLC Trial
Candel Therapeutics announced final Phase 2a results for aglatimagene plus valacyclovir in unresectable stage III/IV NSCLC patients with inadequate ICI response. The treatment showed a median overall survival (mOS) of 24
EQUITY | Oct 01, 2026, 12:08 PM UTC
L
Candel Therapeutics, Inc. (CADL) Phase 3 Subgroup Shows 41% Lower Risk of Recurrence/Death
Candel Therapeutics reported Phase 3 subgroup results showing HR 0.59 (p=0.0034) for recurrence or prostate cancer-specific death with aglatimagene plus EBRT vs placebo, and Phase 2 biomarker data indicating systemic imm
NEWS | Sep 30, 2026, 12:31 PM UTC
L
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) NASDAQ:CADL, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve dis
NEWS | Sep 30, 2026, 12:31 PM UTC
L
Candel Therapeutics, Inc. (CADL) Reports Sustained Immune Remodeling in Phase 3 Prostate Study
Candel Therapeutics reported AI-enabled digital pathology from its completed Phase 3 aglatimagene study showing significantly increased intratumoral lymphocyte infiltration vs placebo more than two years post-EBRT, suppo
NEWS | Sep 30, 2026, 12:08 PM UTC
L
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) NASDAQ:CADL, a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve dis
NEWS | Sep 30, 2026, 12:08 PM UTC
L
CADL: Aglatimagene nears BLA submission after positive phase III data, with focused launch and key catalysts ahead
Two viral immunotherapies are advancing in clinical trials, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned for year-end. The commercial launch will focus on top account
NEWS | Sep 15, 2026, 02:30 PM UTC
L
CADL: Aglatimagene nears BLA submission after positive phase III data, targeting focused launch and key accounts
Two viral immunotherapies are advancing, with aglatimagene showing strong phase III results in prostate cancer and a BLA submission planned by year-end. The launch will focus on top accounts, with positive payer feedback
NEWS | Sep 15, 2026, 02:19 PM UTC
M
Candel Therapeutics plans BLA submission by year-end for aglatimogen in prostate cancer
Candel Therapeutics said a pivotal phase III trial for aglatimogen in prostate cancer met its primary endpoint, supporting a planned BLA submission by year-end. The company expects new biomarker and long-term survivor da
EQUITY | Sep 10, 2026, 08:39 PM UTC
L
Candel appoints Martine Zimmermann as independent director
Candel appointed Martine Zimmermann as an independent member of its board, effective September 8, 2026.
EQUITY | Sep 10, 2026, 12:24 PM UTC
L
Candel Therapeutics appoints Martine Zimmermann, PharmD, to its board
Candel Therapeutics, Inc. said it appointed Martine Zimmermann, PharmD, to its board of directors. The company is a clinical-stage biopharmaceutical focused on multimodal immunotherapies for cancer.
EQUITY | Sep 10, 2026, 12:11 PM UTC
L
Candel Therapeutics appoints Martine Zimmermann to board
EQUITY | Sep 10, 2026, 12:05 PM UTC
L
Candel Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4)
Candel Therapeutics (CADL) announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Candel Therapeutics to present at September investor conferences
Candel Therapeutics says it will present at September investor conferences, per TradingView News.
EQUITY | Aug 26, 2026, 12:07 PM UTC
L
CADL - Candel Therapeutics to Present at September Investor Conferences
CADL - Candel Therapeutics to Present at September Investor Conferences
EQUITY | Aug 26, 2026, 12:05 PM UTC
L
Candel Therapeutics (CADL) reports Q2 2026 financial results
Candel Therapeutics (CADL) reports its second-quarter 2026 financial results along with recent corporate highlights, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 12:05 PM UTC
L
CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
CADL - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
EQUITY | Aug 03, 2026, 12:05 PM UTC
L
CADL - Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
CADL - Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
EQUITY | Jul 29, 2026, 12:05 PM UTC
L
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclovir In Combination With Continued Pembroli
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today a
COMMODITIES | Jun 30, 2026, 12:15 PM UTC
L
CADL Appoints CCO
Candel Therapeutics appoints Mark Sims as Chief Commercial Officer
EQUITY | Jun 25, 2026, 12:05 PM UTC